Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Reduced chronic graft versus host disease after allogeneic HSCT with cryopreserved peripheral blood stem cell grafts: A CIBMTR analysis

Alexandria Maurer, Tao Wang, Zachariah Defilipp, Jakob Devos, Nosha Farhadfar, Pooja Khandelwal, Stephen Spellman, Najla El Jurdi, Stephanie Lee, Robert Soiffer

Blood (2025) 146 (Supplement 1): 933.

https://doi.org/10.1182/blood-2025-933

Published: 2025

Journal Articles

Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants

Pashna Munshi, Tao Wang, Shannon McCurdy, Rajneesh Nath, Cuyler Huffman, Nosha Farhadfar, Zachariah Defilipp, Pooja Khandelwal, Wael Saber, Stephen Spellman, Najla El Jurdi, Stephanie Lee, Zheng Zhou

Blood (2025) 146 (Supplement 1): 931.

https://doi.org/10.1182/blood-2025-931

Published: 2025

Journal Articles

Response dynamics to belumosudil in chronic graft-versus-host disease: Characterizing late responses and organ-specific response expectations from the rockstar study

Zachariah Defilipp, Lauren Rota, Kathy Marshall, Yu Yao, Ran Ji, Alaa Ali

Blood (2025) 146 (Supplement 1): 6004.

https://doi.org/10.1182/blood-2025-6004

Published: 2025

Journal Articles

Can we perform allogeneic hematopoietic cell transplantation (HCT) safely in patients with limited social supports and substantial psychosocial complexity?

Nicolas Trad, Matthew Reynolds, Maya Abdallah, John Mark Sloan, Richard Newcomb, Jennifer D'Alotto, Julie Vanderklish, Nived Subhendu, Michelle Lee, Zachariah Defilipp, Thomas Spitzer, Yi-Bin Chen, Areej El-Jawahri

Blood (2025) 146 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2025-4617

Published: 2025

Journal Articles

Safety and feasibility of 0.6 mg/kg every 4 weeks dosing of axatilimab in patients treated in the AGAVE-201 study

Nosha Farhadfar, Maria Sola Soto, Saurabh Chhabra, Valkal Bhatt, Emily Andersen, Zhenyi Xue, Zachariah Defilipp

Blood (2025) 146 (Supplement 1): 272.

https://doi.org/10.1182/blood-2025-272

Published: 2025

Journal Articles

Trial in progress: A phase 3, randomized, double-blind, placebo-controlled study of axatilimab and corticosteroids as initial treatment for moderate to severe chronic graft-versus-host disease

Zachariah Defilipp, Maureen Bleam, Chuan Tian, Albert Assad

Blood (2025) 146 (Supplement 1): 4256.

https://doi.org/10.1182/blood-2025-4256

Published: 2025

Journal Articles

RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT

Zachariah DeFilipp, Hannah Choe, Yvonne A. Efebera, Ayman Saad, Shatha Farhan, Lazaros Lekakis, Jean A. Yared, Gary Schiller, Markus Y. Mapara, Amer Assal, Ted Gooley, Jack D. Bui, Dana Lee, Hayley Lane, Yi-Bin Chen

Blood (2025) 146 (17): 2037–2046.

https://doi.org/10.1182/blood.2025029584

Published: 2025

Includes: Supplemental data

Journal Articles

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

Zachariah DeFilipp, Haesook T. Kim, Laura W. Knight, Suzanne M. O’Connor, Shilton E. Dhaver, Meghan White, Bhagirathbhai Dholaria, Mark A. Schroeder, Sumithira Vasu, Sameem Abedin, Jooho Chung, Areej El-Jawahri, Matthew J. Frigault, Steven McAfee, Richard A. Newcomb, Paul V. O’Donnell, Thomas R. Spitzer, Yi-Bin Chen, Gabriela S. Hobbs

Blood (2025) 145 (20): 2312–2316.

https://doi.org/10.1182/blood.2024028005

Published: 2025

Includes: Supplemental data

Journal Articles

Can JAK inhibition prevent GVHD?

Zachariah DeFilipp

Blood (2024) 144 (22): 2273–2274.

https://doi.org/10.1182/blood.2024026193

Published: 2024

Journal Articles

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Blood (2024) 144 (Supplement 1): 380.

https://doi.org/10.1182/blood-2024-204010

Published: 2024

Journal Articles

Vitamin A keeps the GVHD away?

Zachariah DeFilipp

Blood (2024) 143 (12): 1067.

https://doi.org/10.1182/blood.2024023828

Published: 2024

Journal Articles

Spatial transcriptomics reveals distinct tissue niches linked with steroid responsiveness in acute gastrointestinal GVHD

Bidish K. Patel, Michael J. Raabe, Evan R. Lang, Yuhui Song, Chenyue Lu, Vikram Deshpande, Linda T. Nieman, Martin J. Aryee, Yi-Bin Chen, David T. Ting, Zachariah DeFilipp

Blood (2023) 142 (21): 1831–1844.

https://doi.org/10.1182/blood.2023020644

Published: 2023

Includes: Supplemental data

Journal Articles

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah Defilipp, David I Lichter, Jonathan U Peled, Marcel R.M. van den Brink, Kelly Brady, Matthew D Puhl, Gabrielle Glick, Brooke Hasson, Barbara H McGovern, Lisa von Moltke, Bina Tejura

Blood (2023) 142 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2023-180119

Published: 2023

Journal Articles

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Blood (2023) 142 (Supplement 1): 1.

https://doi.org/10.1182/blood-2023-186963

Published: 2023

Journal Articles

A Phase II Multicenter Trial of Ruxolitinib to Treat Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation

Zachariah Defilipp, Haesook T. Kim, Guang-Shing Cheng, Saurabh Chhabra, Mehdi Hamadani, Karamjeet S. Sandhu, Betty K. Hamilton, Lia Perez, Catherine J. Lee, Timothy L Brennan, Cassandra Garrelts, Bergin M Brown, Kathleen Gallagher, Areej El-Jawahri, Yi-Bin Chen

Blood (2023) 142 (Supplement 1): 775.

https://doi.org/10.1182/blood-2023-179365

Published: 2023

Journal Articles

Multimodal Mobile Application to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant (HCT) Survivors

Areej El-Jawahri, Jennifer Reese, Lara Traeger, Don Dizon, Sharon Bober, Julie Vanderklish, Richard Newcomb, Zachariah Defilipp, Yi-Bin Chen, Jennifer Temel

Blood (2023) 142 (Supplement 1): 5142.

https://doi.org/10.1182/blood-2023-185776

Published: 2023

Journal Articles

Maintenance Ruxolitinib Is Associated with Low Rates of Chronic Gvhd Requiring Systemic Treatment in Older Adults with AML/MDS Undergoing Allogeneic HCT: Results of a Phase II Multicenter Trial

Zachariah Defilipp, Haesook T. Kim, Laura Knight, Suzanne O'Connor, Meghan White, Bhagirathbhai Dholaria, Mark A. Schroeder, Sumithira Vasu, Sameem Abedin, Areej El-Jawahri, Steven McAfee, Yi-Bin Chen, Gabriela S. Hobbs

Blood (2023) 142 (Supplement 1): 653.

https://doi.org/10.1182/blood-2023-180423

Published: 2023

Journal Articles

Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial

Blood (2023) 142 (Supplement 1): 649.

https://doi.org/10.1182/blood-2023-180142

Published: 2023

Journal Articles

The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd

Blood (2023) 142 (Supplement 1): 3576.

https://doi.org/10.1182/blood-2023-182300

Published: 2023

Journal Articles

Prediction of Graft-Versus-Host Disease (GVHD) in Recipients of Hematopoietic Cell Transplant(alloHCT) from a Single Mismatched Unrelated Donor Using a Highly Multiplexed Proteomics Assay: MHC-Pepseq

Karamjeet S. Sandhu, John Altin, Tao Wang, Jakob Devos, Medhat Askar, Zachariah DeFilipp, Ketevan Gendzekhadze, Carrie L. Kitko, Stephanie J. Lee, Margaret L. MacMillan, Stephen R. Spellman, Ryotaro Nakamura

Blood (2023) 142 (Supplement 1): 4930.

https://doi.org/10.1182/blood-2023-186724

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Reduced chronic graft versus host disease after allogeneic HSCT with cryopreserved peripheral blood stem cell grafts: A CIBMTR analysis

Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants

Response dynamics to belumosudil in chronic graft-versus-host disease: Characterizing late responses and organ-specific response expectations from the rockstar study

Can we perform allogeneic hematopoietic cell transplantation (HCT) safely in patients with limited social supports and substantial psychosocial complexity?

Safety and feasibility of 0.6 mg/kg every 4 weeks dosing of axatilimab in patients treated in the AGAVE-201 study

Trial in progress: A phase 3, randomized, double-blind, placebo-controlled study of axatilimab and corticosteroids as initial treatment for moderate to severe chronic graft-versus-host disease

RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

Can JAK inhibition prevent GVHD?

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Vitamin A keeps the GVHD away?

Spatial transcriptomics reveals distinct tissue niches linked with steroid responsiveness in acute gastrointestinal GVHD

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

A Phase II Multicenter Trial of Ruxolitinib to Treat Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation

Multimodal Mobile Application to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant (HCT) Survivors

Maintenance Ruxolitinib Is Associated with Low Rates of Chronic Gvhd Requiring Systemic Treatment in Older Adults with AML/MDS Undergoing Allogeneic HCT: Results of a Phase II Multicenter Trial

Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial

The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd

Prediction of Graft-Versus-Host Disease (GVHD) in Recipients of Hematopoietic Cell Transplant(alloHCT) from a Single Mismatched Unrelated Donor Using a Highly Multiplexed Proteomics Assay: MHC-Pepseq

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only